Equities analysts predict that Chimerix, Inc. (NASDAQ:CMRX) will report ($0.41) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate coming in at ($0.38). Chimerix reported earnings per share of ($0.39) during the same quarter last year, which suggests a negative year-over-year growth rate of 5.1%. The business is scheduled to announce its next earnings results on Monday, August 14th.

On average, analysts expect that Chimerix will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($1.99) to ($1.55). For the next year, analysts forecast that the firm will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.46) to ($1.49). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Chimerix.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.01. Chimerix had a negative net margin of 1,221.34% and a negative return on equity of 24.07%. The business had revenue of $1.08 million during the quarter, compared to the consensus estimate of $1.56 million.

CMRX has been the topic of a number of research analyst reports. FBR & Co reaffirmed a “hold” rating and issued a $7.00 target price on shares of Chimerix in a report on Monday, May 1st. Cowen and Company reaffirmed a “hold” rating and issued a $6.00 target price on shares of Chimerix in a report on Friday, April 28th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Chimerix presently has a consensus rating of “Hold” and an average price target of $7.55.

Shares of Chimerix (CMRX) traded up 4.13% during trading on Monday, reaching $5.55. The company’s stock had a trading volume of 242,499 shares. The company’s market cap is $258.91 million. Chimerix has a 52-week low of $3.49 and a 52-week high of $6.64. The firm’s 50-day moving average is $4.85 and its 200 day moving average is $5.36.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/chimerix-inc-cmrx-expected-to-post-earnings-of-0-41-per-share/1385092.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Redmile Group LLC boosted its position in shares of Chimerix by 29.3% in the first quarter. Redmile Group LLC now owns 4,325,055 shares of the biopharmaceutical company’s stock worth $27,594,000 after buying an additional 979,096 shares during the last quarter. EcoR1 Capital LLC boosted its position in shares of Chimerix by 136.7% in the fourth quarter. EcoR1 Capital LLC now owns 1,415,687 shares of the biopharmaceutical company’s stock worth $6,512,000 after buying an additional 817,625 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Chimerix by 114.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock worth $6,656,000 after buying an additional 557,927 shares during the last quarter. Morgan Stanley boosted its position in shares of Chimerix by 203.9% in the first quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock worth $3,944,000 after buying an additional 414,717 shares during the last quarter. Finally, Opaleye Management Inc. boosted its position in shares of Chimerix by 50.0% in the fourth quarter. Opaleye Management Inc. now owns 1,170,000 shares of the biopharmaceutical company’s stock worth $5,382,000 after buying an additional 390,000 shares during the last quarter. Institutional investors own 66.84% of the company’s stock.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.